TET1 and acute myeloid leukemia: Jiang et al. [122] showed that the JAK/STAT pathway is involved in TET1 transcription in AML, and by using the STAT inhibitor UC‐514321, they were able to stop aberrant TET1 function in vitro (Fig. 4B).